recombinant alpha-galactosidase A

ApprovedProtein / enzyme

AAssistance Publique - Hôpitaux de Paris

recombinant alpha-galactosidase A is one of 42 small molecule programs targeting Sepsis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SepsisActive, not recruiting

Fabry DiseaseActive, not recruiting

SepsisPhase 2

Active, not recruiting

Fabry DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

308 competitors in Sepsis

#DrugCompanyPhaseTrials

recombinant alpha-galactosidase A

AAssistance Publique - Hôpitaux de Paris

Approved

1 2

Corlanor

Amgen

Preclinical

2 3

Primaxin

Zyvox

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

3 6

Levophed

GGeneral Hospital of Ningxia Medical University

Preclinical

2 7

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

1 8

Levaquin

WWim Janssens

Preclinical

1 9

Jardiance

Boehringer Ingelheim

Preclinical

1 10

Micardis

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 2Not yet recruiting

Sepsis

NCT06381661

Clinical

Trials by Indication[1]

Sepsis1 trial

Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06381661·2,000 enrolled

Fabry Disease1 trial

Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT00487630·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for recombinant alpha-galactosidase A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — recombinant alpha-galactosidase A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for recombinant alpha-galactosidase A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Approved[1]
Company: AAssistance Publique - Hôpitaux de Paris

recombinant alpha-galactosidase A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Sepsis1 trial

Fabry Disease1 trial

References

Drug Info

Quick Facts

Related News